BMC cancer · 2026
A novel Chimeric Antigen Receptor (CAR) - strategy to target EGFRVIII-mutated glioblastoma cells via macrophages.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vera Kristi, Esken Gülen, Hwang Jin Wook, Elbaz Carine, Chaker Diana, Oudrhiri Noufissa, Desterke Christophe, Griscelli Frank, Bennaceur-Griscelli Annelise, Turhan Ali G
Аннотация
BACKGROUND: Autologous chimeric antigen receptor (CAR) expressing T-Cells (CAR-T) have been efficiently used in hematological malignancies but their efficacy in solid tumors remains limited. CAR therapies via the use of macrophages, offer a promising avenue due to their unique ability to infiltrate tumors and to initiate phagocytosis.
METHODS: To generate a preclinical model of CAR-Macs, we have designed a novel CAR-construct to target EGFRVIII-expressing glioblastoma cells (DK-MG) using THP-1 monocytic cell line able to differentiate towards macrophages. The CAR structure comprises a ScFv recognizing specifically EGFRVIII and MEGF10 intracellular domain which enhances tethering and phagocytosis activity.
RESULTS: THP-1 cell line expressing CAR and control constructs were generated via lentiviral transduction followed by generation of monocytes and CAR-expressing M1 macrophages (CAR-Macs). To evaluate their ability of phagocytosis, we co-cultured THP-1 derived WT macrophages or CAR-Macs in the presence of target DK-MG cells. Confocal microscopy experiments revealed highly efficient phagocytosis of DK-MG EGFRVIII cells by CAR-Macs (~ 60%) as compared to WT cells (~ 15%). The killing potential of the anti-EGFRVIII CAR-Macs against the glioblastoma cell line has also been observed using video microscopy. ELISA and LDH assays performed in co-culture supernatants, showed an increase of IL-6 and LDH levels suggesting efficient cytotoxicity via CAR-Macs. Transcriptome analyses performed in purified CAR-Macs, revealed evidence of a molecular signature in favor of successful phagocytosis.
CONCLUSIONS: The model described in this work is suitable for allowing translation to iPSC-derived macrophages to generate clinically applicable future cell therapy approaches in solid tumors expressing mutated variant EGFRVIII.
METHODS: To generate a preclinical model of CAR-Macs, we have designed a novel CAR-construct to target EGFRVIII-expressing glioblastoma cells (DK-MG) using THP-1 monocytic cell line able to differentiate towards macrophages. The CAR structure comprises a ScFv recognizing specifically EGFRVIII and MEGF10 intracellular domain which enhances tethering and phagocytosis activity.
RESULTS: THP-1 cell line expressing CAR and control constructs were generated via lentiviral transduction followed by generation of monocytes and CAR-expressing M1 macrophages (CAR-Macs). To evaluate their ability of phagocytosis, we co-cultured THP-1 derived WT macrophages or CAR-Macs in the presence of target DK-MG cells. Confocal microscopy experiments revealed highly efficient phagocytosis of DK-MG EGFRVIII cells by CAR-Macs (~ 60%) as compared to WT cells (~ 15%). The killing potential of the anti-EGFRVIII CAR-Macs against the glioblastoma cell line has also been observed using video microscopy. ELISA and LDH assays performed in co-culture supernatants, showed an increase of IL-6 and LDH levels suggesting efficient cytotoxicity via CAR-Macs. Transcriptome analyses performed in purified CAR-Macs, revealed evidence of a molecular signature in favor of successful phagocytosis.
CONCLUSIONS: The model described in this work is suitable for allowing translation to iPSC-derived macrophages to generate clinically applicable future cell therapy approaches in solid tumors expressing mutated variant EGFRVIII.